MedTrace Logo

Circulating Tumour Cells as Biomarkers to Predict Prostate Cancer Metastasis for Treatment Stratification of Cancer

NCT05533515 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2025-08-19

No results posted yet for this study

Summary

The goal of this study is to establish the value of Circulating Tumour Cell (CTC) positivity in predicting post-RP treatment failure, including BCR and new lesions detected by cancer imaging. We plan to recruit participants who will undergo Radical Prostatectomy (RP). Participants will have their blood samples taken just before surgery and 3 months after the surgery to test for CTCs. Then participants will be followed-up for cancer progression information at 3 month intervals for the first year then yearly intervals after that. Their PSA will be observed over time.

Conditions

Interventions

DIAGNOSTIC_TEST

CTC Blood Test

We will draw blood to measure the level of Circulating Tumour Cells

Sponsors & Collaborators

  • University College London Hospitals

    collaborator OTHER

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Greg Shaw · University College London Hospitals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-08
Primary Completion
2024-03-05
Completion
2024-03-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05533515 on ClinicalTrials.gov